For example, the CheckMate 143 trial, the first large randomized study targeting programmed death-1 (PD-1) signaling in GBM, demonstrated that nivolumab did not extend OS in patients with recurrent GBM compared to bevacizumab (29). Here, PDCD1 is linked to glioblastoma.